Department of Medical Education & Biomedical Informatics, University of Washington, Seattle, WA, USA.
BMC Bioinformatics. 2010 Oct 28;11 Suppl 9(Suppl 9):S10. doi: 10.1186/1471-2105-11-S9-S10.
In pursuing personalized medicine, pharmacogenomic (PGx) knowledge may help guide prescribing drugs based on a person's genotype. Here we evaluate the feasibility of incorporating PGx knowledge, combined with clinical data, to support clinical decision-making by: 1) analyzing clinically relevant knowledge contained in PGx knowledge resources; 2) evaluating the feasibility of a rule-based framework to support formal representation of clinically relevant knowledge contained in PGx knowledge resources; and, 3) evaluating the ability of an electronic medical record/electronic health record (EMR/EHR) to provide computable forms of clinical data needed for PGx clinical decision support. Findings suggest that the PharmGKB is a good source for PGx knowledge to supplement information contained in FDA approved drug labels. Furthermore, we found that with supporting knowledge (e.g. IF age <18 THEN patient is a child), sufficient clinical data exists in University of Washington's EMR systems to support 50% of PGx knowledge contained in drug labels that could be expressed as rules.
在追求个性化医学的过程中，药物基因组学（PGx）知识可能有助于根据个体的基因型指导药物处方。在这里，我们通过以下方式评估纳入 PGx 知识，结合临床数据来支持临床决策的可行性：1）分析 PGx 知识资源中包含的临床相关知识；2）评估基于规则的框架支持正式表示 PGx 知识资源中包含的临床相关知识的可行性；3）评估电子病历/电子健康记录（EMR/EHR）提供 PGx 临床决策支持所需的可计算临床数据的能力。研究结果表明，PharmGKB 是补充 FDA 批准药物标签中信息的 PGx 知识的良好来源。此外，我们发现，在华盛顿大学的 EMR 系统中存在支持知识（例如，如果年龄<18 岁，则患者为儿童），可以支持 50%的药物标签中可表达为规则的 PGx 知识。
